A 44-year-old male with schizophrenia who smokes 1.5 packs per day was started on varenicline 1 mg twice daily eight weeks ago as part of a comprehensive smoking cessation program that includes motivational interviewing and a quit-date approach. He set a quit date at week two and initially reduced to five cigarettes per day by week four. However, at this eight-week evaluation, he reports he has increased back to approximately 12 cigarettes per day following a period of increased psychotic symptom intensity that required a temporary increase in his risperidone dose. He denies any worsening of mood or suicidal ideation. His expired carbon monoxide level is 22 ppm. He expresses frustration but states he still wants to quit. The PMHNP is evaluating the smoking cessation treatment outcome at this point. Which evaluation is most appropriate?